Faeth Therapeutics, Inc. Lease, Cost
Faeth Therapeutics, Inc. (FTH) reported Lease, Cost of $1.25 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-04
- Faeth Therapeutics, Inc. lease, cost for the quarter ending 2026-06-30 was $630.00K, a 2.93% decline year-over-year.
- Faeth Therapeutics, Inc. lease, cost for the quarter ending 2026-03-31 was $617.00K, a 8.86% decline year-over-year.
- Faeth Therapeutics, Inc. lease, cost for the quarter ending 2025-12-31 was $617.00K, a 21.10% decline year-over-year.
- Faeth Therapeutics, Inc. lease, cost for the quarter ending 2025-09-30 was $625.00K, a 24.15% decline year-over-year.
- Faeth Therapeutics, Inc. lease, cost for fiscal 2025 was $2.57M, a 22.44% decline from fiscal 2024.
- Faeth Therapeutics, Inc. lease, cost for fiscal 2024 was $3.31M, a 2.33% decline from fiscal 2023.
- Faeth Therapeutics, Inc. lease, cost for fiscal 2023 was $3.39M, a 5.41% increase from fiscal 2022.
- Faeth Therapeutics, Inc. lease, cost for fiscal 2022 was $3.22M.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $630.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.25M 10-Q · filed 2026-08-04 | $1.86M derived: sum of 3 quarters · filed 2026-08-04 | $2.49M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $617.00K 10-Q · filed 2026-05-15 | $1.23M derived: sum of 2 quarters · filed 2026-05-15 | $1.86M derived: sum of 3 quarters · filed 2026-05-15 | $2.51M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $617.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.24M derived: sum of 2 quarters · filed 2026-03-30 | $1.89M derived: sum of 3 quarters · filed 2026-08-04 | $2.57M 10-K · filed 2026-03-30 |
| 2025-09-30 | $625.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.27M derived: sum of 2 quarters · filed 2026-08-04 | $1.95M 10-Q · filed 2025-11-14 | $2.73M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $649.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.33M 10-Q · filed 2026-08-04 | $2.11M derived: sum of 3 quarters · filed 2026-08-04 | $2.93M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $677.00K 10-Q · filed 2026-05-15 | $1.46M derived: sum of 2 quarters · filed 2026-05-15 | $2.28M derived: sum of 3 quarters · filed 2026-05-15 | $3.15M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $782.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.61M derived: sum of 2 quarters · filed 2026-03-30 | $2.47M derived: sum of 3 quarters · filed 2026-03-30 | $3.31M 10-K · filed 2026-03-30 |
| 2024-09-30 | $824.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.69M derived: sum of 2 quarters · filed 2025-11-14 | $2.53M 10-Q · filed 2025-11-14 | $3.37M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $867.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.71M 10-Q · filed 2025-08-05 | $2.54M derived: sum of 3 quarters · filed 2025-08-05 | $3.37M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $838.00K 10-Q · filed 2025-05-06 | $1.68M derived: sum of 2 quarters · filed 2025-05-06 | $2.50M derived: sum of 3 quarters · filed 2025-05-06 | $3.41M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $840.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $1.66M derived: sum of 2 quarters · filed 2025-03-28 | $2.57M derived: sum of 3 quarters · filed 2025-03-28 | $3.39M 10-K · filed 2025-03-28 |
| 2023-09-30 | $823.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $1.73M derived: sum of 2 quarters · filed 2023-11-07 | $2.55M 10-Q · filed 2023-11-07 | $3.35M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $910.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $1.73M 10-Q · filed 2023-08-03 | $2.53M derived: sum of 3 quarters · filed 2023-08-03 | $3.34M derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | $817.00K 10-Q · filed 2023-05-09 | $1.62M derived: sum of 2 quarters · filed 2023-05-09 | $2.43M derived: sum of 3 quarters · filed 2023-05-09 | $3.22M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | $801.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $1.61M derived: sum of 2 quarters · filed 2023-03-29 | $2.41M derived: sum of 3 quarters · filed 2023-03-29 | $3.22M 10-K · filed 2023-03-29 |
| 2022-09-30 | $808.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.60M derived: sum of 2 quarters · filed 2022-11-08 | $2.42M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $797.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.61M 10-Q · filed 2022-08-09 | ||
| 2022-03-31 | $810.00K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |